Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Pfizer stock is a new Buy at Guggenheim

Published 02/23/2024, 05:41 AM
Updated 02/23/2024, 07:19 AM
© Reuters.  Pfizer (PFE) stock is the new Buy at Guggenheim

A team of Guggenheim analysts started research coverage on Pfizer (NYSE:PFE) with a Buy rating and a 12-month target price of $36, implying roughly 30% upside from Thursday’s closing price.

PFE rose 0.5% in premarket trading.

Over the past two years, Pfizer's stock has notably lagged behind expectations, a period marked by heightened investor anticipation for the company's COVID-19 vaccine, Comirnaty, and its oral antiviral treatment, Paxlovid, amid the pandemic.

“We believe expectations for Pfizer's COVID assets have now appropriately come down and, while several of their other largest revenue generators are also facing challenges, we see an opportunity for near-term estimates to increase,” said analysts.

This opportunity depends on whether Pfizer can “successfully commercialize large potential opportunities, such as Padcev in 1L bladder cancer and Abrysvo for prophylactic vaccination against RSV,” they added.

Currently, with investor expectations for PFE being quite low, any clinical success from notable pipeline assets like vepdegestrant, VLA15, and ponsegromab could boost investor confidence and enhance long-term forecasts, the broker commented.

“Beyond the products that have already launched, we believe Pfizer now has an interesting mix of internally-developed and externally-acquired assets that can drive potential upside in 2027+, if successfully developed,” the analysts wrote.

Meanwhile, the existing dividend yield of approximately 6% offers stock support as management progresses with its strategy.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.